Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates
暂无分享,去创建一个
Robert Krysiak | Andrzej Madej | B. Okopień | A. Madej | D. Belowski | R. Krysiak | M. Zieliński | Z. Herman | Bogusław Okopień | Jan Kowalski | Dariusz Belowski | Marek Zieliński | Zbigniew S Herman | J. Kowalski
[1] G. Hunninghake,et al. Inhibition of Rho Family GTPases Results in Increased TNF-α Production After Lipopolysaccharide Exposure 1 , 2003, The Journal of Immunology.
[2] B. Okopień,et al. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia , 2003, European Journal of Clinical Pharmacology.
[3] D. Gómez-Coronado,et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. , 2000, Atherosclerosis.
[4] Tzung-Dau Wang,et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. , 2003, Atherosclerosis.
[5] Y. Horsmans,et al. Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors , 1996, Clinical pharmacokinetics.
[6] Michael R. Müller,et al. Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[7] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[8] M. Haberka,et al. Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia , 2005, Journal of cardiovascular pharmacology.
[9] Robert Kleemann,et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. , 2003, Blood.
[10] Robert Kleemann,et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. , 2004, Blood.
[11] A. Wessel,et al. Interleukin-1 and related proteins in cardiovascular disease in adults and children. , 2001, Shock.
[12] S. Frøland,et al. Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors , 2004, Circulation.
[13] S. Janciauskiene,et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. , 2002, Pharmacological research.
[14] R. Mortensen. C-reactive protein, inflammation, and innate immunity , 2001, Immunologic research.
[15] J. Hallenbeck. The many faces of tumor necrosis factor in stroke , 2002, Nature Medicine.
[16] J. Spence,et al. Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) , 1998, Clinical pharmacokinetics.
[17] Shuiping Zhao,et al. Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[18] H. Waterham,et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. , 2002, Arthritis and rheumatism.
[19] T. Awata,et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. , 2000, Life sciences.
[20] S. Basili,et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.
[21] Robert Kleemann,et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation , 2003 .
[22] K. Arnesen,et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.
[23] P. Libby,et al. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. , 2004, The American journal of medicine.
[24] O. Grip,et al. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. , 2000, European journal of pharmacology.
[25] K. Labuzek,et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. , 2004, Atherosclerosis.
[26] A. Terashi,et al. Effects of an HMG-CoA reductase inhibitor on cytokine production by human monocytes/macrophages. , 1995, Nihon Ika Daigaku zasshi.
[27] A. Weverling-Rijnsburger,et al. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. , 2000, Atherosclerosis.
[28] E. Yeh,et al. Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.
[29] M. Netea,et al. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors. , 1998, Atherosclerosis.
[30] J. Berger,et al. Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 Cells , 2000 .
[31] G. Zhou,et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. , 2000, Biochemical and biophysical research communications.
[32] Jian‐Jun Li,et al. Simvastatin inhibits interleukin‐6 release in human monocytes stimulated by C‐reactive protein and lipopolysaccharide , 2003, Coronary artery disease.
[33] T. Meinertz,et al. Zytokine in der Pathogenese der Atherosklerose , 2002, Deutsche medizinische Wochenschrift.
[34] P. M. Davis,et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. , 2001, International immunopharmacology.
[35] B. Binder,et al. Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[36] O. Grip,et al. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. , 2002, Inflammation research : official journal of the European Histamine Research Society ... [et al.].